Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/223114
COMPARTIR / EXPORTAR:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Campo DC Valor Lengua/Idioma
dc.contributor.authorÁlvarez, Andreaes_ES
dc.contributor.authorFernández Llamas, Lucíaes_ES
dc.contributor.authorIglesias, Beatrizes_ES
dc.contributor.authorRodríguez-Carrio, Javieres_ES
dc.contributor.authorGarcía Suárez, María Pilares_ES
dc.date.accessioned2020-11-18T11:01:54Z-
dc.date.available2020-11-18T11:01:54Z-
dc.date.issued2020-01-30-
dc.identifier.citationFuture Virology 14: 12 (2020)es_ES
dc.identifier.issn1746-0808-
dc.identifier.urihttp://hdl.handle.net/10261/223114-
dc.description.abstractThe use of phages to kill pathogenic bacteria is an old practice to cure infectious diseases. The current antibiotic crisis has boosted phage therapy research, but its application in hospitals is still very limited. Here, we analyze the problems that need to be solved to go forward with this renewed therapy, hoping that it can be useful for patients suffering from an incurable infection. We would like to emphasize that phage therapy is right now at a crossroads. This may be similar to what happened a century ago with the arrival of antibiotics, but now we do not have such a good alternative. Therefore, let us not waste this opportunity, even if a radical change in our health strategy is necessary.es_ES
dc.description.sponsorshipThis study was funded by grants AGL2015-65673-R (MINECO/FEDER/EU, Spain), EU ANIWHA ERA-NET (BLAAT ID: 67)/PCIN2017-001 (AEI/FEDER/EU, Spain), Proyecto Intramural CSIC 201770E016, IDI/2018/000119 (Asturias Innovation 2018–2020, Principado de Asturias, Spain) and FEDER/EU. P Garcia and A Rodrıguez are members of the bacteriophage network FAGOMA and the FWO Vlaanderen funded ‘Phagebiotics’ research community (WO.016.14)es_ES
dc.language.isoenges_ES
dc.publisherFuture Medicinees_ES
dc.relationinfo:eu-repo/grantAgreement/MINECO/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016/AGL2015-65673-Res_ES
dc.relation.isversionofPostprint-
dc.rightsopenAccessen_EN
dc.subjectAntibiotic resistancees_ES
dc.subjectHospitalses_ES
dc.subjectInfectious diseaseses_ES
dc.subjectNew antibioticses_ES
dc.subjectPhage therapyes_ES
dc.titlePhage therapy: Unexpected drawbacks to reach hospitalses_ES
dc.typeartículoes_ES
dc.identifier.doi10.2217/fvl-2019-0154-
dc.description.peerreviewedPeer reviewedes_ES
dc.relation.publisherversionhttp://dx.doi.org/10.2217/fvl-2019-0154es_ES
dc.contributor.funderMinisterio de Economía y Competitividad (España)es_ES
dc.contributor.funderEuropean Commissiones_ES
dc.contributor.funderPrincipado de Asturiases_ES
dc.relation.csices_ES
oprm.item.hasRevisionno ko 0 false*
dc.identifier.funderhttp://dx.doi.org/10.13039/501100003329es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/501100000780es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/100011941es_ES
dc.contributor.orcidFernández, Lucía [0000-0002-7383-7595]es_ES
dc.contributor.orcidGarcía Suárez, María Pilar [0000-0003-1213-8165]es_ES
dc.type.coarhttp://purl.org/coar/resource_type/c_6501es_ES
item.languageiso639-1en-
item.fulltextWith Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.grantfulltextopen-
item.openairetypeartículo-
Aparece en las colecciones: (IPLA) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato
Phage_therapy.docx43,17 kBMicrosoft Word XMLVisualizar/Abrir
Show simple item record

CORE Recommender

SCOPUSTM   
Citations

5
checked on 21-abr-2024

WEB OF SCIENCETM
Citations

4
checked on 24-feb-2024

Page view(s)

127
checked on 24-abr-2024

Download(s)

76
checked on 24-abr-2024

Google ScholarTM

Check

Altmetric

Altmetric


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.